PG4 + PA-001

PG4 + PA-001 is an investigational multivalent pneumococcal conjugate vaccine (PnC) formulation developed by Pfizer for the prevention of *Streptococcus pneumoniae* infections. The vaccine candidate, PG4, utilizes conjugate technology similar to Pfizer's Prevnar series but is designed to expand serotype coverage beyond the current 20-valent vaccine (Prevnar 20). PA-001 is an experimental component, likely an adjuvant or formulation enhancer, being evaluated in clinical trials to optimize the vaccine's safety, tolerability, and immunogenicity. The vaccine works by inducing a T-cell dependent immune response against bacterial capsular polysaccharides. It is currently in Phase 1 and Phase 2 clinical development, with studies evaluating its performance in healthy adults and pediatric populations, including infants and toddlers.

Brand names

PG4 vaccinePG-4 vaccinePG 4 vaccine

Other names

Multivalent pneumococcal conjugate vaccine (PG4)